Immune infiltrate predicts response to αPD1/αCTLA4 but not αPD1 and distinguishes programs of primary resistance in metastatic melanoma

While immune-checkpoint blockade (ICB) has revolutionized treatment of metastatic melanoma, the identification of robust biomarkers to predict the relative efficacy of single versus combination ICB has been challenging. We performed a meta-analysis of eight cohorts of patients treated with anti–PD-1 ( n = 290), anti–CTLA-4 ( n = 175), and combination anti–PD-1/anti–CTLA-4 ( n = 51) with pretreatment tumor sequencing and clinical annotations. Surprisingly, the increased response rate to combination anti–PD-1/anti–CTLA-4 compared to anti–PD-1 monotherapy was observed only in highly immune infiltrated tumors, and not in immune-low tumors. Stratifying tumors by high or low frequency of immune cells also distinguished context-dependent programs of primary resistance to single and combination ICB. Notably, hypoxia-related pathways were enriched in nonresponders to anti–PD-1 ICB in immune-high, but not immune-low, tumors. Using an independent cohort of patients with scRNA-seq data, we observed that correlates of hypoxia were associated with increased stromal tumor receptor-ligand interactions. As proof of concept, selective inhibition of HIF-2α, a component of the hypoxia pathway and highly expressed in endothelial cells and fibroblasts, in combination with anti–PD-1, controlled tumor growth in mouse models of highly immune-infiltrated tumors but not poorly immune-infiltrated tumors. Our work demonstrates how stratification by tumor immune characteristics and clinical features can lead to the rational discovery of novel therapeutic targets.

Authors

Institutions

Publication Details

Journal
Science Advances
Published
2026-11-20
DOI
https://doi.org/10.1126/sciadv.aed0035
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Immune infiltrate predicts response to αPD1/αCTLA4 but not αPD1 and distinguishes programs of primary resistance in metastatic melanoma

Genevieve Marie Boland, Amy Y. Huang, Emily J. Robitschek, Arlene H. Sharpe et al.
1 links
Science Advances
Cancer Immunotherapy and Biomarkers
article

Immune infiltrate predicts response to αPD1/αCTLA4 but not αPD1 and distinguishes programs of primary resistance in metastatic melanoma

Genevieve Marie Boland, Amy Y. Huang, Emily J. Robitschek, Arlene H. Sharpe, Tyler J. Aprati, Jiekun Yang, Kelly P. Burke, Cora A. Ricker, Marc Glettig, Elizabeth Iannotti Buchbinder, Peter R. Fatouros, Shuyun Xu, Giuseppe Tarantino, Gordon James Freeman, Frank Stephen Hodi, Christine Guo Lian, Doris Fu, Natalie I. Vokes, Jiajia Chen, David Liu, M Kellis, Li‐Lun Ho, Yiwen He, Kyriaki Galani, Valeria Rosado, Lynn Meiger, Ryan Porter, Jonathan M. Li, Cassia Wang
article en

Abstract

While immune-checkpoint blockade (ICB) has revolutionized treatment of metastatic melanoma, the identification of robust biomarkers to predict the relative efficacy of single versus combination ICB has been challenging. We performed a meta-analysis of eight cohorts of patients treated with anti–PD-1 ( n = 290), anti–CTLA-4 ( n = 175), and combination anti–PD-1/anti–CTLA-4 ( n = 51) with pretreatment tumor sequencing and clinical annotations. Surprisingly, the increased response rate to combination anti–PD-1/anti–CTLA-4 compared to anti–PD-1 monotherapy was observed only in highly immune infiltrated tumors, and not in immune-low tumors. Stratifying tumors by high or low frequency of immune cells also distinguished context-dependent programs of primary resistance to single and combination ICB. Notably, hypoxia-related pathways were enriched in nonresponders to anti–PD-1 ICB in immune-high, but not immune-low, tumors. Using an independent cohort of patients with scRNA-seq data, we observed that correlates of hypoxia were associated with increased stromal tumor receptor-ligand interactions. As proof of concept, selective inhibition of HIF-2α, a component of the hypoxia pathway and highly expressed in endothelial cells and fibroblasts, in combination with anti–PD-1, controlled tumor growth in mouse models of highly immune-infiltrated tumors but not poorly immune-infiltrated tumors. Our work demonstrates how stratification by tumor immune characteristics and clinical features can lead to the rational discovery of novel therapeutic targets.

Science AdvancesVol. 12(47)
Rutgers, The State University of New Jersey (US), Broad Institute (US), Brigham and Women's Hospital (US), The University of Texas MD Anderson Cancer Center (US), Harvard University (US), ETH Zurich (CH), Massachusetts General Hospital (US), Dana-Farber Cancer Institute (US), Massachusetts Institute of Technology (US)
American Association for Cancer Research, Doris Duke Charitable Foundation, Cancer Prevention and Research Institute of Texas, American-Italian Cancer Foundation, Dr. Miriam and Sheldon G. Adelson Medical Research Foundation, Barr Foundation, Society for Immunotherapy of Cancer, National Institutes of Health, National Cancer Institute
Good health and well-being
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon